Supernus' nonstimulant ADHD drug Qelbree gains approval for adult use
Up to 90% of the children that are diagnosed with attention deficit hyperactivity disorder retain the diagnosis into adulthood. Now, those adults will have another nonstimulant option for treatment, as the FDA approved an expanded indication for the use of Supernus Pharmaceuticals’ product in adults.
The drug, Qelbree, is now approved for everyone above the age of 6 diagnosed with ADHD. There are roughly 16 million people in the US with the disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.